Molbio Diagnostics shares rose over 5% on October 1, after HDFC Mutual Fund acquired a 1.99% stake. The stock gained approximately 71% since its IPO, and Jefferies assigned a ‘Buy’ rating, setting a target price of ₹1,600, indicating over 98% upside potential.
Molbio Diagnostics shares jump 5% as HDFC MF buys 1.99% stake via bulk deal | Newly listed stock up 71% from IPO price
Published ·

Keep reading
Related stories







